In MDAMB468 cells, Lovastatin lactone had a cell proliferation IC50 of 9 μg/mL after 48 hours. Lovastatin treatment produced time-dependent ERK activation in BC3 and BCBL1 cells. In HUVECs, Lovastatin treatment was associated with both downregulated and upregulated genes. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cell proliferation response in MDAMB468 cells
Cell-based study · MDAMB468 [1]
MDAMB468 cells were treated with lovastatin lactone for 48 hours. The cell proliferation IC50 was 9 μg/mL.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 hours
- Reported limits
- Not stated in the sentences used: dose, route, vehicle.
Methods and source locations
Compound reported in the paper: Lovastatin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > MTT assay (S12, S13); Results > Lovastatin inhibits cell proliferation (S88); Figure 1 legend (S140, S142)
Cell proliferation: Cell proliferation; comparator: control cells — Results > Lovastatin inhibits cell proliferation (S88); Figure 1 legend (S140)
Time-dependent ERK activation in BC3 and BCBL1 cells
Cell-based study · BC3 [2]
BC3 cells were treated with 30 μM Lovastatin, and phosphorylated ERK was evaluated by western blotting. Time-dependent ERK activation was reported in both BC3 and BCBL1 cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 30 μM
- Exposure duration
- for 24 and 48 h
- Method
- treated
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Lovastatin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
EXPERIMENTAL PROCEDURES > Cell culture, reagents and treatments (S7); RESULTS > Lovastatin activates ERK1/2 by reducing STAT3 tyrosine phosphorylation in PEL cells (S48); FIGURE 2 legend (S90)
ERK1/2 (pERK) was evaluated by western blotting: ERK1/2 (pERK) was evaluated by western blotting; comparator: not (CT) — RESULTS > Lovastatin activates ERK1/2 by reducing STAT3 tyrosine phosphorylation in PEL cells (S48); FIGURE 2 legend (S90)
Gene expression changes in HUVECs
Cell-based study · HUVECs [3]
HUVECs were treated with 0.5 µM Lovastatin. After 2 h, 12 genes were downregulated and 178 genes were upregulated; after 24 h, 33 genes were downregulated and 77 genes were upregulated.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 µM
- Exposure duration
- 2 and 24 h of treatment
- Vehicle
- 0.1% dimethyl sulfoxide
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Lovastatin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Untitled > Cell culture (S9); Materials and methods > Untitled > cDNA microarray (S20); Results > Untitled > Effects of lovastatin on the gene expression profile of HUVECs (S59, S61, S62)
gene expression profile: gene expression profile; comparator: vehicle-treated group — Results > Untitled > Effects of lovastatin on the gene expression profile of HUVECs (S59, S61, S62)